US › Healthcare

Tandem Diabetes Care Inc (TNDM)

US · Healthcare · Medical Devices

$20.20+0.45%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$247.2M
Revenue YoY
+5.5%
Net profit
$-20.4M
Profit YoY
+84.4%
EPS
$-0.30
EPS estimate
$-0.44
Net margin
-8.2%

EPS came in at -0.30 against a street estimate of -0.44 — a beat of 31.8%.

Key statistics

Market cap
$1.34B
Forward P/E
1,111.1
P/B
10.09
Book value
$1.93
EPS (TTM)
$-1.37
52-week high
$29.65
52-week low
$9.98
50-day MA
$16.52
200-day MA
$19.01
Beta
1.58

Analyst view

Analysts rate Tandem Diabetes Care Inc a buy (10 buy, 10 hold, 1 sell out of 21) with an average price target of $28.52.

Shareholding

Insiders
0.97%
Institutions
117.95%

Largest institutional holders

FundStake
BlackRock Inc15.60%
Vanguard Group Inc10.71%
Sessa Capital, L.P6.90%
Vanguard Portfolio Management, LLC5.83%
ArrowMark Colorado Holdings, LLC (ArrowMark Partners)4.53%
Vanguard Capital Management, LLC4.43%
GW&K Investment Management, LLC3.92%
State Street Corp3.88%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Tandem Diabetes Care Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.